Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jun 19;7:3831. doi: 10.1038/s41598-017-03940-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Tunicamycin induced UPR and PARP cleavage in the presence of TUDCA: HepG2 cells were treated with12 µM tunicamycin, 2 mM TUDCA or with TUDCA and tunicamycin for different time periods as shown in the figure and were processed as described in Materials and Methods. Panel A represents time course analysis of different UPR marker proteins in cells treated with 2 mM TUDCA for indicated time periods. Panel B represents UPR status in cells pretreated with 2 mM TUDCA for 15 h and then incubated with 12 µM tunicamycin for different time periods (8, 15, 24, and 36 h) as indicated in the figure. Panel C represents morphology of HepG2 cells in response to corresponding treatments as mentioned in panel B.